On April 1, 2020, The FDA announced that it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market due to contamination with nitrosodimethylamine (NDMA). This article is only of historical interest.

Ranitidine was FDA-approved for both adults and children aged 1 month to 16 years. Ranitidine, over-the-counter for self-care use without a prescription, was only FDA-approved in children older than 12 years.

**FDA-Approved Ranitidine Indications**

- Benign gastric ulcer disease, short-term, and maintenance

- Duodenal ulcer disease, short-term, and maintenance

- Erosive esophagitis

- Hypersecretory conditions (e.g., Zollinger-Ellison, systemic mastocytosis, multiple endocrine adenoma syndrome)

- Gastroesophageal reflux disease (GERD)

- Non-ulcer dyspepsia, indigestion, heartburn, and sour stomach

**Non-FDA-Approved Ranitidine Indications**

- Anaphylaxis

- NSAID-induced ulcer prophylaxis

- Stress ulcer prophylaxis

- Taxane-related urticaria prophylaxis

- Aspiration prophylaxis during obstetric anesthesia